Clinical trials: Endocrine System Disorder
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus
A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.
- Trial name
- NCT00521378
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Diasome Pharmaceuticals
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT05443568)
- Testing
- Oral semaglutide
- Where
- Israel
- Volunteers
- 155 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
T2DM, Diabete Type 2
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
- Conditions
- T2DM, Diabete Type 2, DM
- Trial name
- NCT07093476
- Testing
- Metformin, Alogliptin, empagliflozin
- Where
- South Korea
- Volunteers
- 171 people
- Sponsor
- Celltrion
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and South America. The aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin NPH plus human soluble insulin in subjects with type 1…
- Trial name
- NCT01486940
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 75 sites in Argentina, Croatia and 13 more
- Volunteers
- 598 people
- Sponsor
- Novo Nordisk A/S
Chronic Ulcers, Diabetic Foot Ulcers (DFU)
Case Series of StimLabs Dehydrated Human Umbilical Cord Particulate for Acute and Chronic Wounds
The purpose of this observational case series is to assess the use of Corplex P as a resorbable particulate device used to cover, protect, and provide a moist wound environment when added to the standard of care treatment of…
- Conditions
- Chronic Ulcers, Diabetic Foot Ulcers (DFU), DFU, Ulcer
- Trial name
- NCT07414368
- Testing
- Corplex P is used to cover, protect, and provide a moist wound environment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- StimLabs
Diabetes Mellitus, Type 2
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
Single ascending dose first time in human study for GZR18 in healthy subjects
- Trial name
- NCT05328726
- Testing
- GZR-18
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Type I Diabetes
Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device
This study observes the continuous measurement of breathing patterns, heart rate, restlessness, and tremor in sleep using the EarlySense ES 16 device as a tool in the management of hypoglycemia in pediatric type I diabetes…
- Trial name
- NCT00361608
- Testing
- EarlySense ES 16
- Where
- Israel
- Sponsor
- EarlySense Ltd.
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
- Trial name
- DENALI (NCT05128825)
- Testing
- azenosertib
- Where
- 89 sites in United States, Australia and 7 more
- Volunteers
- 310 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Type 2 Diabetes, Obesity
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
- Trial name
- NCT01114438
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Morphic Medical Inc.
Diabetic Foot Ulcer (DFU), Amnio-Maxx
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
- Trial name
- NCT07209475
- Testing
- Amnio-Maxx® Dual Layer Amnion Patch, Standard of Care (Investigator Choice)
- Where
- 8 sites in United States
- Volunteers
- 248 people
- Sponsor
- Royal Biologics
Diabetic Retinopathy
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.
- Trial name
- NCT00090519
- Testing
- ruboxistaurin
- Where
- 84 sites in United States, Australia and 15 more
- Volunteers
- 731 people
- Sponsor
- Chromaderm, Inc.
Diabetic Foot Ulcer
Treatment of Diabetic Foot Ulcers With AUP1602-C
This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.
- Trial name
- NCT04281992
- Testing
- AUP1602-C
- Where
- 2 sites in Germany, Poland
- Volunteers
- 26 people
- Sponsor
- Aurealis Oy
Healthy
Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06291874 in healthy volunteers.
- Trial name
- NCT01794364
- Testing
- PF-06291874
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
Primary Objective: -To demonstrate the efficacy of a fixed combination of glimepiride + metformin in terms of HbA1c reduction, during 24-week treatment period in patients with inadequately controlled type 2 diabetes mellitus.
- Trial name
- LEGEND (NCT01699932)
- Testing
- Glimepiride+metformin (Amaryl M®) - HOE4900
- Where
- 13 sites in Lebanon, Russia and 1 more
- Volunteers
- 167 people
- Sponsor
- Sanofi
Advanced or Metastatic Pancreatic Adenocarcinoma
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
A dose finding study in locally advanced and/or metastatic pancreatic cancer patients
- Trial name
- NCT00560963
- Testing
- everolimus
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
To evaluate the similarity of the efficacy and safety of semaglutide injection (QLG2065) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
- Trial name
- NCT05950516
- Testing
- Semaglutide, Semaglutide Pen Injector [Ozempic]
- Where
- China
- Volunteers
- 478 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
- Trial name
- NCT03724981
- Testing
- Dulaglutide Pen, Semaglutide Pen
- Where
- 14 sites in United States
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.